topical ghk-cu Copper Peptide 0.5% (topical foam) GHK-Cu Rx Protocol

This fragment is designed to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) without elevating IGF-1 or affecting glucose metabolism

What is the CAS number for AOD-9604

Synaptogenesis & dendritic spines Investigated in rodent tissue and cell models for its reported ability to increase dendritic spine density preclinical only, and the primary source assays were retracted in 2025

CagriSema is cagrilintide + semaglutide , a fixed-dose once-weekly combination developed by Novo Nordisk and studied in the REDEFINE program ( REDEFINE 1, NCT05567796 )

Results of therapy vary by patient and type of treatment